AEHR Soars 20% on AI Chip Testing Boom
💡 Puntos Clave
Aehr Test Systems' pivot from EVs to AI processors drove record bookings and a 20% stock surge, with revenue expected to triple next year.
What Happened: Record Bookings and a Strategic Pivot
Aehr Test Systems (AEHR) saw its stock jump 20.9% this week after reporting stellar fiscal fourth-quarter earnings. The company, which makes testing equipment for semiconductors, announced record bookings of $60.7 million in the quarter, bringing second-half bookings to $97.9 million—well above its guidance range of $60 million to $80 million.
CEO Gayn Erickson highlighted that the fastest-growing markets are now AI accelerators, CPUs, and network processors, which made up 71% of annual revenue. Just two years ago, over 95% of Aehr's business came from silicon carbide chips for electric vehicles (EVs).
The company's backlog now stands at $100 million, and management expects fiscal 2027 revenue of $130 million to $150 million, up from $50 million in fiscal 2026. Aehr also anticipates returning to profitability next year.
This shift from EVs to AI is a major strategic move, positioning Aehr to capitalize on the booming demand for AI chip testing. The market rewarded the news with a sharp rally, reflecting optimism about the company's new direction.
Why It Matters: AI Chip Testing Is a Growth Engine
Aehr's pivot is significant because the AI chip market is growing much faster than the EV silicon carbide market. As AI processors become more complex, reliability testing becomes critical, and Aehr's equipment is essential for ensuring chips don't fail in data centers.
The record bookings and strong guidance suggest that Aehr is gaining traction with major AI chipmakers. This could lead to sustained revenue growth and profitability, making the stock an attractive play on the AI infrastructure buildout.
For investors, the key takeaway is that Aehr is no longer tied to the struggling EV market. Instead, it's riding the AI wave, which could drive multiple expansions and higher valuations.
However, the stock is still speculative, with a market cap around $1 billion. If the company executes on its guidance, it could be a multi-bagger. But any slowdown in AI spending or loss of its lead customer could reverse the gains.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight
Aehr is a strong buy for investors seeking exposure to AI chip testing growth.
The company's successful pivot from EVs to AI, combined with record bookings and a $100 million backlog, positions it for explosive revenue growth. Management's guidance of $130-150 million in FY2027 implies a tripling of revenue, and the return to profitability adds credibility. Risks include customer concentration and AI spending cycles, but the risk-reward is favorable.
¿Cómo Me Afecta?
